Special Issue "Human Papillomavirus Vaccines"
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 7834
2. Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
Interests: HPV pathogenesis; HPV preventive vaccine; L1-VLP vaccine; HPV therapeutic vaccine; PDT effect against HPV infection
Special Issues, Collections and Topics in MDPI journals
Around the world, the number of cervical cancer cases per year is estimated as 570,000 women, with 310,000 women dying of cervical cancer in 2018. In Japan, the number of cervical cancer cases in young women aged 20–39 is increasing, as is the mortality rate, with a tendency which is totally different from that in the rest of world.
In 2017, about 2800 women across Japan died of cervical cancer, more than 1200 of whom were under the age of 65, the so-called active generation. This is an extremely alarming trend. In addition, the active recommendation of an HPV vaccine that can effectively prevent cervical cancer has been withheld for a while—in fact, HPV vaccination has been suspended for the public in Japan.
Meanwhile, data on the safety and efficacy of HPV vaccines have been collected from Japan and overseas. Therefore, the Japan Society of Obstetrics and Gynecology requested prompt resumption of the active recommendation of the HPV vaccine.
The main aim of this Special Issue is to help to prevent uterine cervical cancer. For the prevention of uterine cervical cancer, there are two categories: primary and secondary prevention. As primary prevention of uterine cervical cancer, HPV vaccines are used for the prevention of HPV infection worldwide. This category includes the efficacy and safety of the 9-valent vaccine against cervical cancer, the current status of 4-valent vaccines in Japan and issues with their spread, and the development and clinical application of a broad-spectrum L2-VLP HPV vaccine.
As secondary prevention of uterine cervical cancer, the diagnosis and management of CIN is performed. This category includes the diagnosis of CIN using conventional methods (i.e., cytology, HPV test, and histology), diagnosis using new methods (i.e., immune-cytochemistry and miRNA), and obstetric issues of cervical conization used for the diagnosis and treatment of CIN, the treatment of CIN using PDT with Photofrin and Laserphyrin, the treatment of CIN using 5ALA-PDT, the therapeutic effect of PDT on HPV infection, and the treatment of CIN with a new method, that is, HPV therapeutic vaccines.
We are interested in a broad area of research, focusing primarily on the management of CIN and HPV eradication strategies for the prevention of uterine cervical cancer. In addition, we are calling for manuscripts dealing with vaccine trials (preclinical and clinical) and strategies to develop a more effective HPV vaccine. We aim to present a combination of manuscripts dealing with different vital aspects of HPV, which can be exploited to develop more effective eradication strategies for HPV infection.
Dr. Masaru Sakamoto
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- 4-valent HPV vaccine
- 9-valent HPV vaccine
- HPV L1-VLP vaccine
- HPV L2-VLP vaccine
- HPV therapeutic vaccine